Kyntra Bio, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
4.05M
on 2026-06-30, from 3.98M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-25 reverse split; each bar's tip shows the count as filed.
Newest
S-3 of 2024-06-28. Not read yet. S-3 ↗
$30.0M
BofA Securities, agreement of 2025-02-24. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
9.6 quarters
$91.3M on 2026-06-30 ÷ $9.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
Raised: 2 of its filings are not read yet.
Also on file: a 1-for-25 reverse split, 2025-06-10 8-K ↗